Association of Autoantibody Concentrations and Trajectories With Lupus Nephritis Histologic Features and Treatment Response
Arthritis & Rheumatology · 2024
DOI: 10.1002/art.42941 ↗Kurz gefasst
Fachartikel in der Zeitschrift Arthritis & Rheumatology, 2024. Verfasst von Andrea Fava und 18 weiteren Autor:innen. Beteiligte Einrichtung: Johns Hopkins University, Baltimore, Maryland. Hauptthemen laut MEDLINE: Lupus Nephritis, Autoantibodies, Complement C1q. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAMS NIH HHS, NHLBI NIH HHS, NIDDK NIH HHS.
Abstract (Originalsprache)
Objective
Autoantibodies are a hallmark of lupus nephritis (LN), but their association with LN classes and treatment response are not adequately known. In this study, we quantified circulating autoantibodies in the Accelerating Medicines Partnership LN longitudinal cohort to identify serological biomarkers of LN histologic classification and treatment response and how these biomarkers change over time based on treatment response.
Methods
Peripheral blood samples were collected from 279 patients with systemic lupus erythematosus undergoing diagnostic kidney biopsy based on proteinuria. Of these, 268 were diagnosed with LN. Thirteen autoantibody specificities were measured by bead‐based assays (Bio‐Rad Bioplex 2200) and anti‐C1q by enzyme‐linked immunosorbent assay at the time of biopsy (baseline) and at 3, 6, and 12 months after biopsy. Clinical response was determined at 12 months.
Results
Proliferative LN (International Society of Nephrology/Renal Pathology Society class III/IV±V, n = 160) was associated with higher concentrations of anti‐C1q, anti‐chromatin, anti–double‐stranded DNA (dsDNA), and anti–ribosomal P autoantibodies compared to nonproliferative LN (classes I/II/V/VI, n = 108). Anti‐C1q and‐dsDNA were independently associated with proliferative LN. In proliferative LN, higher baseline anti‐C1q levels predicted complete response (area under the curve [AUC] 0.72; P = 0.002) better than baseline proteinuria (AUC 0.59; P = 0.21). Furthermore, all autoantibody levels except for anti‐La/SSB decreased over 12 months in patients with proliferative, but not membranous, LN with a complete response.
Conclusion
Baseline levels of anti‐C1q and anti‐dsDNA may serve as noninvasive biomarkers of proliferative LN, and anti‐C1q may predict complete response at the time of kidney biopsy. In addition, tracking autoantibodies over time may provide further insights into treatment response and pathogenic mechanisms in patients with proliferative LN. image
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Johns Hopkins University, Baltimore, Maryland.
- Oklahoma Medical Research Foundation, Oklahoma City.
- New York University School of Medicine, New York City.
- New York University Langone Health, New York City.
- The Feinstein Institutes for Medical Research, Manhasset, New York.
- The Feinstein Institutes for Medical Research, Manhasset, and Donald and Barbara Zucker School of Medicine, Northwell Health, Hempstead, New York.
ORCID-Profile: Andrea Fava, H Michael Belmont, Anne Davidson, Michelle Petri, Jill Buyon, Judith A James
Förderung
- NIAMS NIH HHS
- NHLBI NIH HHS
- NIDDK NIH HHS
- NIAID NIH HHS
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
- National Institute of Diabetes and Digestive and Kidney Diseases
- Division of Intramural Research
Zitieren
APA
Fava, A., Wagner, C. A., Guthridge, C. J., Kheir, J., Macwana, S., DeJager, W., Gross, T., Izmirly, P., Belmont, H. M., Diamond, B., Davidson, A., Utz, P. J., Weisman, M. H., Magder, L. S., Accelerating Medicines Partnership Rheumatoid Arthritis and Systemic Lupus Erythematosus (AMP RA/SLE) Network, Guthridge, J. M., Petri, M., Buyon, J., & James, J. A. (2024). Association of Autoantibody Concentrations and Trajectories With Lupus Nephritis Histologic Features and Treatment Response. Arthritis & Rheumatology. https://doi.org/10.1002/art.42941
Vancouver
Fava A, Wagner CA, Guthridge CJ, Kheir J, Macwana S, DeJager W, et al. Association of Autoantibody Concentrations and Trajectories With Lupus Nephritis Histologic Features and Treatment Response. Arthritis & Rheumatology. 2024. doi:10.1002/art.42941
BibTeX
@article{Fava2024,
author = {Fava, Andrea and Wagner, Catriona A and Guthridge, Carla J and Kheir, Joseph and Macwana, Susan and DeJager, Wade and Gross, Tim and Izmirly, Peter and Belmont, H Michael and Diamond, Betty and Davidson, Anne and Utz, Paul J and Weisman, Michael H and Magder, Laurence S and Accelerating Medicines Partnership Rheumatoid Arthritis and Systemic Lupus Erythematosus (AMP RA/SLE) Network, Accelerating Medicines Partnership Rheumatoid Arthritis and Systemic Lupus Erythematosus (AMP RA/SLE) Network and Guthridge, Joel M and Petri, Michelle and Buyon, Jill and James, Judith A},
title = {Association of Autoantibody Concentrations and Trajectories With Lupus Nephritis Histologic Features and Treatment Response},
journal = {Arthritis & Rheumatology},
year = {2024},
doi = {10.1002/art.42941}
}
EUVIMED